Hudson Bay Capital Management LP decreased its position in shares of uniQure (NASDAQ:QURE - Free Report) by 72.5% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 175,000 shares of the biotechnology company's stock after selling 460,500 shares during the period. Hudson Bay Capital Management LP owned about 0.36% of uniQure worth $3,090,000 at the end of the most recent quarter.
Other hedge funds have also recently bought and sold shares of the company. Invesco Ltd. lifted its stake in uniQure by 453.2% during the 4th quarter. Invesco Ltd. now owns 613,601 shares of the biotechnology company's stock worth $10,836,000 after acquiring an additional 502,684 shares in the last quarter. Sanders Morris Harris LLC lifted its stake in uniQure by 50.0% during the 4th quarter. Sanders Morris Harris LLC now owns 102,104 shares of the biotechnology company's stock worth $1,803,000 after acquiring an additional 34,034 shares in the last quarter. Franklin Resources Inc. purchased a new stake in uniQure during the 3rd quarter worth about $7,360,000. Oppenheimer & Co. Inc. purchased a new stake in uniQure during the 4th quarter worth about $320,000. Finally, Palumbo Wealth Management LLC purchased a new stake in uniQure during the 4th quarter worth about $437,000. Institutional investors and hedge funds own 78.83% of the company's stock.
Insider Buying and Selling
In related news, CEO Matthew C. Kapusta sold 28,341 shares of the firm's stock in a transaction that occurred on Tuesday, March 4th. The stock was sold at an average price of $10.29, for a total transaction of $291,628.89. Following the transaction, the chief executive officer now owns 651,454 shares in the company, valued at $6,703,461.66. This trade represents a 4.17% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Christian Klemt sold 10,438 shares of the firm's stock in a transaction that occurred on Tuesday, March 4th. The stock was sold at an average price of $10.29, for a total value of $107,407.02. Following the transaction, the chief financial officer now owns 217,730 shares in the company, valued at $2,240,441.70. This represents a 4.57% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 90,830 shares of company stock worth $961,401 in the last quarter. 4.74% of the stock is owned by insiders.
Wall Street Analysts Forecast Growth
Several equities research analysts have weighed in on the company. Royal Bank of Canada restated an "outperform" rating and set a $24.00 price target on shares of uniQure in a report on Tuesday, January 21st. Chardan Capital restated a "buy" rating and set a $38.00 price target on shares of uniQure in a report on Monday, May 12th. HC Wainwright restated a "buy" rating and set a $70.00 price target on shares of uniQure in a report on Monday, April 21st. Wells Fargo & Company cut their price target on uniQure from $35.00 to $30.00 and set an "equal weight" rating on the stock in a report on Friday, February 28th. Finally, Guggenheim restated a "buy" rating and set a $28.00 price target on shares of uniQure in a report on Monday, May 12th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, uniQure has an average rating of "Moderate Buy" and an average price target of $37.82.
Get Our Latest Stock Analysis on QURE
uniQure Stock Up 3.4%
Shares of QURE traded up $0.45 during mid-day trading on Friday, reaching $13.70. The company's stock had a trading volume of 1,614,113 shares, compared to its average volume of 1,877,379. uniQure has a 12-month low of $3.73 and a 12-month high of $19.18. The stock has a market cap of $750.43 million, a PE ratio of -2.76 and a beta of 0.10. The company has a debt-to-equity ratio of 0.92, a current ratio of 6.51 and a quick ratio of 6.51. The company's 50 day moving average is $12.31 and its 200 day moving average is $12.28.
uniQure (NASDAQ:QURE - Get Free Report) last released its quarterly earnings results on Friday, May 9th. The biotechnology company reported ($0.82) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.07) by $0.25. The firm had revenue of $1.57 million for the quarter, compared to the consensus estimate of $5.93 million. uniQure had a negative return on equity of 188.82% and a negative net margin of 837.80%. Equities analysts anticipate that uniQure will post -3.75 EPS for the current fiscal year.
uniQure Company Profile
(
Free Report)
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.
See Also
Before you consider uniQure, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and uniQure wasn't on the list.
While uniQure currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
